Schedule 13G ownership disclosure
INDAPTUS THERAPEUTICS INC
Common Stock · CUSIP: 45339J105
Event date: 2025-02-13
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- YA II PN, Ltd.
Shares: 1,410,916.00 · Class: 9.99%
- YA Global Investments II (U.S.), LP
Shares: 1,410,916.00 · Class: 9.99%
- Yorkville Advisors Global, LP
Shares: 1,410,916.00 · Class: 9.99%
- Yorkville Advisors Global II, LLC
Shares: 1,410,916.00 · Class: 9.99%
- YAII GP, LP
Shares: 1,410,916.00 · Class: 9.99%
- YAII GP II, LLC
Shares: 1,410,916.00 · Class: 9.99%
- Mark Angelo
Shares: 1,410,916.00 · Class: 9.99%
- SC-Sigma Global Partners, LP
Shares: 1,410,916.00 · Class: 9.99%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-25-014739
- Form type
- SCHEDULE 13G
- Filer
- Indaptus Therapeutics, Inc.
- CIK
- CIK 1857044
- Filed
- Feb 18, 2025
- Reporting period
- Feb 13, 2025
- Description
- Schedule 13G beneficial ownership